Welcome to our dedicated page for Rigel Pharmaceuticals news (Ticker: RIGL), a resource for investors and traders seeking the latest updates and insights on Rigel Pharmaceuticals stock.
Rigel Pharmaceuticals Inc (NASDAQ: RIGL) is a clinical-stage biotechnology company pioneering small molecule therapies for hematologic disorders, cancer, and immune diseases. This news hub provides investors and healthcare professionals with rigorously verified updates on RIGL's clinical developments, regulatory milestones, and strategic partnerships.
Key resources include earnings announcements, trial result disclosures, FDA submissions, and licensing agreements. Our curated collection enables stakeholders to track the progress of oral kinase inhibitors and novel therapeutic candidates through development pipelines.
Bookmark this page for centralized access to Rigel's latest scientific advancements and business updates. All content is maintained to reflect current developments while preserving historical context for longitudinal analysis of the company's progress.
Rigel Pharmaceuticals (Nasdaq: RIGL) reported strong Q2 2025 financial results, with total revenue of $101.7 million, including net product sales of $58.9 million (76% YoY growth) and contract revenues of $42.7 million. The company generated $59.6 million in net income and increased its cash position to $108.4 million.
Key highlights include TAVALISSE sales of $40.1 million (52% YoY growth), GAVRETO sales of $11.8 million, and REZLIDHIA sales of $7.0 million (36% YoY growth). Rigel raised its 2025 guidance, projecting total revenue of $270-280 million, including net product sales of $210-220 million.
The company completed enrollment in Phase 1b study of R289 for R/R lower-risk MDS and expects to share updated data and initiate dose expansion later this year.
Rigel Pharmaceuticals (Nasdaq: RIGL), a biotechnology company focused on hematologic disorders and cancer therapies, will report its second quarter 2025 financial results after market close on Tuesday, August 5, 2025.
The company will host a conference call and webcast at 4:30 p.m. Eastern Time to discuss financial results and provide a business update. Investors can join via phone or access the webcast through Rigel's investor relations website, where it will remain available for replay for 90 days.
Rigel Pharmaceuticals (NASDAQ: RIGL) has announced the granting of inducement awards to new employees under NASDAQ Listing Rule 5635(c)(4). The company granted a total of 23,075 stock options and restricted stock units to 10 non-executive employees. These equity awards will vest over a four-year period with a one-year cliff.
Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL), a commercial stage biotechnology company specializing in hematologic disorders and cancer treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. CEO Raul Rodriguez will deliver a company overview on June 4, 2025, at 12:50 p.m. ET in New York. The presentation will be accessible via live webcast through Rigel's Investor Relations website.
Founded in 1996 and headquartered in South San Francisco, Rigel focuses on developing novel therapies for patients with blood disorders and cancer. Interested parties can access the presentation through www.rigel.com.
For GAVRETO in RET fusion-positive NSCLC:
- Overall response rate: 70.3%
- Median duration of response: 19.1 months
- Median overall survival: 44.3 months
- Median progression-free survival: 13.1 months
For REZLIDHIA in mIDH1 R/R AML:
- Higher response rates in patients with 1-2 prior regimens vs ≥3 prior therapies
- 50% overall response rate in primary refractory patients
- Demonstrated efficacy across IDH1-R132 mutation types
Rigel Pharmaceuticals (Nasdaq: RIGL) has scheduled its first quarter 2025 financial results announcement and business update for Tuesday, May 6, 2025, after market close. The company will host a live conference call and webcast at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Investors can join the call through two options:
- Phone: 877-407-3088 (domestic) or 201-389-0927 (international)
- Webcast: Available through the Investor Relations section at www.rigel.com
Rigel, founded in 1996 and based in South San Francisco, is a biotechnology company focused on developing therapies for hematologic disorders and cancer. The webcast will be archived and accessible for replay through the company website for 90 days following the call.
Rigel Pharmaceuticals (Nasdaq: RIGL) has announced the granting of inducement awards under its Inducement Plan, as approved by the company's Compensation Committee. The grants, made in accordance with NASDAQ Listing Rule 5635(c)(4), consist of 23,350 stock options and restricted stock units awarded to seven non-executive employees.
These equity awards will vest over a four-year period with a one-year cliff vesting schedule. The grants serve as inducement material for employees entering into employment with Rigel, a biotechnology company founded in 1996 that focuses on developing therapies for hematologic disorders and cancer.
Rigel Pharmaceuticals (Nasdaq: RIGL) has reached a settlement agreement with Annora Pharma and Hetero Labs regarding patent litigation for its drug TAVALISSE® (fostamatinib disodium hexahydrate). The litigation arose from Annora's submission of an Abbreviated New Drug Application to the FDA for a generic version of TAVALISSE.
Under the settlement terms, Annora will receive a license to sell its generic product in Q2 2032 or earlier under certain circumstances. All ongoing litigation between the parties regarding TAVALISSE patents pending in New Jersey has been terminated. TAVALISSE is indicated for treating thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
Rigel Pharmaceuticals (NASDAQ: RIGL) has appointed Mark W. Frohlich, M.D. to its Board of Directors. Dr. Frohlich brings over 25 years of experience in developing cellular immunotherapies for cancer treatment, with expertise in clinical drug development and translational research.
Currently serving as CEO of Indapta Therapeutics, Dr. Frohlich previously led portfolio strategy at Juno Therapeutics and served as CMO at Dendreon , where he led the development and regulatory approval of PROVENGE®. His background includes positions at UCSF as an assistant adjunct professor of hematology/oncology, with degrees from Yale College and Harvard Medical School.
Dr. Frohlich will contribute to advancing Rigel's hematology and oncology pipeline, particularly focusing on the IRAK1/4 and IDH1 inhibitor programs for lower-risk myelodysplastic syndrome and glioma treatments respectively.
FAQ
What is the current stock price of Rigel Pharmaceuticals (RIGL)?
What is the market cap of Rigel Pharmaceuticals (RIGL)?
